A puzzling phenomenon: Patients report a rebound of COVID-19 symptoms after taking the antiviral Paxlovid

The Boston Globe reports that people taking the new Emergency Use Authorized treatment Paxlovid, made by Pfizer, is leading to a relapse of their Covid19 symptoms.  The only other “Authorized” anti-viral drugs Molnupiravir, sold by Merck, has not been warmly embraced by other nations, citing its safety profile and Gilead’s Remdesivir has earned the nick name “Run death is near” by nurses experienced in its use.

Pfizer’s trials of Paxlovid showed this “rebound” in symptoms around day 10 or 14 of treatment.

These are the two drugs currently “Authorized” to treat Covid19.  Mono-clonal antibodies seem to have been fazed out or highly restricted.  The FDA continues to be relatively silent about ivermectin, a cheap and safe drug that studies in over 100,000 people around the world has shown to be of value.

The FDA continues to push drugs, gene manipulating therapies (Covid19 vaccines), Molnupiravir and Paxlovid anti-virals that are fresh out of drug designers labs.  These drugs have no long term safety data and proscribing them in mass on the public is akin to treating them like laboratory animals.

No wonder long Covid19 keeps getting media attention.  It is becoming clearer that this syndrome has, at least, in some cases an origin in the novel EUA drugs massively promoted and mandated around the world.